Cytochrome 4Z1 Expression is Associated with Poor Prognosis in Colon Cancer Patients

• Published in: OncoTargets and therapy Vol. 14; pp. 5249 - 5260
• Main Authors: Al-Saraireh, Yousef M, Alshammari, Fatemah O F O, Youssef, Ahmed M M, Al-Sarayreh, Sameeh, Almuhaisen, Ghadeer H, Alnawaiseh, Nedal, Al-Shuneigat, Jehad M, Alrawashdeh, Hamzeh M
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2021; Taylor & Francis Ltd; Dove
• Subjects: Angiogenesis; Antibodies; Benign; Biomarkers; Breast cancer; Cancer; Cancer patients; Care and treatment; Chemotherapy; Colon cancer; Colorectal cancer; Cytochrome; Cytochrome P-450; Enzymes; Health aspects; Immunohistochemistry; Laboratories; Lymph nodes; Lymphatic system; Medical prognosis; Metabolites; Metastases; Metastasis; Mortality; Original Research; Peptides; Prognosis; Radiation therapy; Survival; Tumors; United Kingdom > UK; United States > US; cytochrome 4Z1; cancer; cytochrome P450; immunohistochemistry; colon cancer
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S332037

Colon cancer is a leading cause of mortality worldwide. It has a relatively poor prognosis; therefore, new therapies are needed. One of the tumour-related enzymes that has gained considerable interest is CYP4Z1. This enzyme has been expressed in many tumours and has been hypothesized as a potential biomarker or target for novel anticancer therapies. CYP4Z1 overexpression was immunohistochemically examined in a large panel of colon tissue types including normal, benign, primary and metastatic ones, and the enzyme's relation to histopathological features and patient survival was evaluated. A high CYP4Z1 expression was observed in benign, primary and metastatic colon tissues compared to a weak or lack of expression in normal tissues. Importantly, there was a significant differential in CYP4Z1 expression where it was stronger in metastatic, primary and benign, respectively ( < 0.05). A significantly high rate of CYP4Z1 expression was found in high histological grades and late stages of the disease, where its expression was more evident in patients with metastasis in the lymph nodes ( < 0.05). Interestingly, CYP4Z1 expression was identified an independent prognostic predictor of poor overall survival of colon cancer patients (p = 0.003). CYP4Z1 was distinctly overexpressed in benign, primary and metastatic colon tissues compared to corresponding normal tissues. This differential in CYP4Z1 expression across different types of colon tissues strongly supports CYP4Z1 as potential biomarker and target for novel anticancer therapy development.